Kiora Pharmaceuticals, Inc. (KPRX)

Kiora Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	-	16.02	-	-	-
Gross Profit	-	16.02	-	-	-
Selling, General & Admin	5.75	5.54	4.66	8.28	5.32
Research & Development	10.78	7.84	4.03	3.45	5.35
Other Operating Expenses	-3.69	-1.87	3.9	0.58	3.56
Total Operating Expenses	12.83	11.51	12.59	12.31	14.24
Operating Income	-12.83	4.51	-12.59	-12.31	-14.24
Interest Income	0.89	1.25	0.17	0.06	0
Interest Expense	-0.02	-0.02	-0.01	-0.01	-0.01
Other Non-Operating Income (Expense)	-0.16	-0.08	0	-1.44	0.55
Total Non-Operating Income (Expense)	0.71	1.15	0.16	-1.39	0.54
Pretax Income	-12.12	5.66	-12.42	-13.7	-13.96
Provision for Income Taxes	-1.28	2.07	0.09	-0.11	-0.19
Net Income	-10.84	3.59	-13.04	-13.58	-13.77
Net Income Attributable to Preferred Dividends	-	-	0.53	-	-
Net Income to Common	-10.84	3.59	-13.04	-13.58	-13.77
Shares Outstanding (Basic)	4	4	1	0	0
Shares Outstanding (Diluted)	4	4	1	0	0
Shares Change (YoY)	-0.51%	666.73%	561.21%	203.74%	110.04%
EPS (Basic)	-2.60	0.93	-24.25	-166.95	-514.08
EPS (Diluted)	-2.64	0.87	-24.25	-166.95	-514.08
Shares Outstanding	3.76	3	0.54	0.2	0.04
Free Cash Flow	-10.07	8.55	-9.56	-10.43	-10.74
Free Cash Flow Per Share	-2.45	2.07	-17.76	-128.16	-400.89
Gross Margin	-	100.00%	-	-	-
Operating Margin	-	28.15%	-	-	-
Profit Margin	-	22.44%	-	-	-
FCF Margin	-	53.39%	-	-	-
EBITDA	-12.81	4.53	-12.54	-12.27	-14.19
EBITDA Margin	-	28.27%	-	-	-
EBIT	-12.83	4.51	-12.59	-12.31	-14.24
EBIT Margin	-	28.15%	-	-	-
Effective Tax Rate	10.58%	36.49%	-0.73%	0.83%	1.38%

Updated Mar 25, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q